CA3130245A1 - Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof - Google Patents
Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof Download PDFInfo
- Publication number
- CA3130245A1 CA3130245A1 CA3130245A CA3130245A CA3130245A1 CA 3130245 A1 CA3130245 A1 CA 3130245A1 CA 3130245 A CA3130245 A CA 3130245A CA 3130245 A CA3130245 A CA 3130245A CA 3130245 A1 CA3130245 A1 CA 3130245A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- alkyl
- cycloalkyl
- group
- alkoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/504—Pyridazines; Hydrogenated pyridazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910124584.6 | 2019-02-19 | ||
| CN201910124584 | 2019-02-19 | ||
| CN201910437878 | 2019-05-24 | ||
| CN201910437878.4 | 2019-05-24 | ||
| CN201910932095.3 | 2019-09-29 | ||
| CN201910932095 | 2019-09-29 | ||
| PCT/CN2020/074696 WO2020168939A1 (zh) | 2019-02-19 | 2020-02-11 | 杂环化合物、包含其的药物组合物及其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3130245A1 true CA3130245A1 (en) | 2020-08-27 |
Family
ID=72143544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3130245A Pending CA3130245A1 (en) | 2019-02-19 | 2020-02-11 | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220144847A1 (https=) |
| EP (1) | EP3929198A4 (https=) |
| JP (2) | JP7615056B2 (https=) |
| KR (1) | KR20210131314A (https=) |
| CN (3) | CN117263945A (https=) |
| AU (1) | AU2020226422C1 (https=) |
| BR (1) | BR112021016299A2 (https=) |
| CA (1) | CA3130245A1 (https=) |
| CL (1) | CL2021002205A1 (https=) |
| CO (1) | CO2021011023A2 (https=) |
| IL (1) | IL285378B2 (https=) |
| MX (1) | MX2021009971A (https=) |
| PH (1) | PH12021552004A1 (https=) |
| SA (1) | SA521430084B1 (https=) |
| SG (1) | SG11202107848TA (https=) |
| WO (1) | WO2020168939A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022022398A1 (zh) * | 2020-07-28 | 2022-02-03 | 四川科伦博泰生物医药股份有限公司 | 一种嘧啶类化合物的盐和晶型及其制备方法 |
| KR20230159367A (ko) * | 2021-03-24 | 2023-11-21 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 키나아제 약물 내성 돌연변이와 관련된 질병의 치료에있어서의 헤테로사이클릭 화합물의 용도 및 그 방법 |
| CN114235976B (zh) * | 2021-11-09 | 2023-11-03 | 暨南大学 | 一种含氮杂环有机化合物中间产物的合成和分析方法 |
| CN120897743A (zh) | 2023-05-19 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物治疗与ret基因改变相关疾病的用途和方法 |
| WO2025256440A1 (zh) * | 2024-06-14 | 2025-12-18 | 四川科伦博泰生物医药股份有限公司 | 含杂环化合物富马酸盐的制备方法 |
| WO2026017002A1 (zh) * | 2024-07-16 | 2026-01-22 | 四川科伦博泰生物医药股份有限公司 | 以杂环化合物为活性成分的药物组合物、其制备方法及用途 |
| GB202410599D0 (en) | 2024-07-19 | 2024-09-04 | Ellipses Pharma Ltd | Therapeutics useful synergistic combinations |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA200707227B (en) * | 2005-02-28 | 2009-08-26 | Japan Tobacco Inc | Novel aminopyridine compound with syk inhibitory activity |
| BRPI0607062A2 (pt) | 2005-02-28 | 2009-08-04 | Japan Tobacco Inc | composto de aminopiridina com atividade inibidora de syk, composição farmacêutica e agente terapêutico compreendendo os mesmos |
| WO2008013622A2 (en) * | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US20080234267A1 (en) * | 2007-03-20 | 2008-09-25 | Karen Elizabeth Lackey | Compounds and Methods of Treatment |
| JP2010208945A (ja) * | 2007-06-01 | 2010-09-24 | Mitsubishi Tanabe Pharma Corp | 複素環化合物 |
| ES2539170T3 (es) | 2010-01-12 | 2015-06-26 | Ab Science | Inhibidores de quinasas de oxazol |
| JP2013107824A (ja) | 2010-03-17 | 2013-06-06 | Dainippon Sumitomo Pharma Co Ltd | 新規単環ピリミジン誘導体 |
| EP2634176A4 (en) * | 2010-10-28 | 2014-04-16 | Nippon Shinyaku Co Ltd | PYRIDINE DERIVATIVE AND MEDICINAL AGENT |
| US9145391B2 (en) * | 2011-05-10 | 2015-09-29 | Merck Sharp & Dohme Corp. | Bipyridylaminopyridines as Syk inhibitors |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| SI3371171T1 (sl) | 2015-11-02 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitorji ret |
| TWI704148B (zh) | 2016-10-10 | 2020-09-11 | 美商亞雷生物製藥股份有限公司 | 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
| WO2018136661A1 (en) | 2017-01-18 | 2018-07-26 | Andrews Steven W | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS |
-
2020
- 2020-02-11 JP JP2021571055A patent/JP7615056B2/ja active Active
- 2020-02-11 AU AU2020226422A patent/AU2020226422C1/en active Active
- 2020-02-11 CN CN202311221283.8A patent/CN117263945A/zh active Pending
- 2020-02-11 CN CN202311264080.7A patent/CN117327078A/zh active Pending
- 2020-02-11 WO PCT/CN2020/074696 patent/WO2020168939A1/zh not_active Ceased
- 2020-02-11 EP EP20760123.8A patent/EP3929198A4/en active Pending
- 2020-02-11 BR BR112021016299-2A patent/BR112021016299A2/pt unknown
- 2020-02-11 KR KR1020217022806A patent/KR20210131314A/ko active Pending
- 2020-02-11 US US17/431,930 patent/US20220144847A1/en active Pending
- 2020-02-11 CA CA3130245A patent/CA3130245A1/en active Pending
- 2020-02-11 MX MX2021009971A patent/MX2021009971A/es unknown
- 2020-02-11 SG SG11202107848TA patent/SG11202107848TA/en unknown
- 2020-02-11 PH PH1/2021/552004A patent/PH12021552004A1/en unknown
- 2020-02-11 IL IL285378A patent/IL285378B2/en unknown
- 2020-02-11 CN CN202080009954.2A patent/CN113316578B/zh active Active
-
2021
- 2021-08-17 SA SA521430084A patent/SA521430084B1/ar unknown
- 2021-08-18 CL CL2021002205A patent/CL2021002205A1/es unknown
- 2021-08-20 CO CONC2021/0011023A patent/CO2021011023A2/es unknown
-
2024
- 2024-12-27 JP JP2024231551A patent/JP7821259B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| NZ778907A (en) | 2025-05-30 |
| JP2025060928A (ja) | 2025-04-10 |
| IL285378B2 (en) | 2025-11-01 |
| PH12021552004A1 (en) | 2022-09-05 |
| US20220144847A1 (en) | 2022-05-12 |
| CO2021011023A2 (es) | 2021-09-09 |
| CN113316578A (zh) | 2021-08-27 |
| AU2020226422C1 (en) | 2026-04-02 |
| CN113316578B (zh) | 2023-10-31 |
| WO2020168939A1 (zh) | 2020-08-27 |
| AU2020226422B2 (en) | 2025-07-31 |
| IL285378A (en) | 2021-09-30 |
| IL285378B1 (en) | 2025-07-01 |
| JP2022521859A (ja) | 2022-04-12 |
| EP3929198A4 (en) | 2022-11-16 |
| JP7821259B2 (ja) | 2026-02-26 |
| CN117263945A (zh) | 2023-12-22 |
| CL2021002205A1 (es) | 2022-04-22 |
| JP7615056B2 (ja) | 2025-01-16 |
| SG11202107848TA (en) | 2021-08-30 |
| MX2021009971A (es) | 2021-10-13 |
| AU2020226422A1 (en) | 2021-09-09 |
| BR112021016299A2 (pt) | 2021-10-13 |
| EP3929198A1 (en) | 2021-12-29 |
| KR20210131314A (ko) | 2021-11-02 |
| SA521430084B1 (ar) | 2025-05-01 |
| CN117327078A (zh) | 2024-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3130245A1 (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| AU2024201128B2 (en) | Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof | |
| JP2020525525A (ja) | Ｒｈｏ−関連プロテインキナーゼ阻害剤、ｒｈｏ−関連プロテインキナーゼ阻害剤を含む医薬組成物、当該医薬組成物の調製方法及び使用 | |
| CN118055933B (zh) | 选择性parp1抑制剂及其应用 | |
| JP2015516460A (ja) | Ａｂｌ１、ａｂｌ２およびｂｃｒ−ａｂｌ１の活性を阻害するためのベンズアミド誘導体 | |
| CN116143757B (zh) | 一种可降解btk激酶的多功能化合物、组合物及应用 | |
| WO2020186220A1 (en) | Compounds as inhibitors of macrophage migration inhibitory factor | |
| KR102920599B1 (ko) | 항종양 활성을 갖는 화합물 및 이의 용도 | |
| EP4351560A1 (en) | Anticancer compounds | |
| JP2024511389A (ja) | キナーゼ薬剤耐性変異に関連する疾患を治療するための複素環式化合物の使用及び方法 | |
| CN111377873B (zh) | 氨基嘧啶化合物及其制备方法和用途 | |
| CN112574201B (zh) | 芳基胺类化合物、包含其的药物组合物及其制备方法和用途 | |
| CN113166109B (zh) | 氨基吡啶类化合物及其制备方法和用途 | |
| WO2023004376A1 (en) | Nitrile sumo inhibitors and uses thereof | |
| RU2828045C2 (ru) | Гетероциклическое соединение, фармацевтическая композиция, содержащая его, способ его получения и его применение | |
| KR20230158659A (ko) | Ctla-4 소분자 분해제 및 그 응용 | |
| HK40051009A (en) | Heterocyclic compound, pharmaceutical composition comprising same, preparation method therefor, and use thereof | |
| CN117126140A (zh) | 具有蛋白激酶抑制活性的杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| EA050235B1 (ru) | Соединения и их применение в виде ингибиторов gpr183 | |
| HK40051009B (zh) | 杂环化合物、包含其的药物组合物及其制备方法和用途 | |
| HK1138587A (en) | Thiazoles and pyrazoles useful as kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231123 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241217 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241217 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241217 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250417 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250417 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250721 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251223 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260129 |